<DOC>
	<DOCNO>NCT00777946</DOCNO>
	<brief_summary>This study ass safety efficacy combination aliskiren/amlodipine patient adequately control aliskiren alone</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Combination Aliskiren/Amlodipine Patients Not Adequately Responding Aliskiren Alone</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Newly diagnose patient patient treated hypertension within 4 week prior Visit 1 must mean sit Diastolic Blood Pressure ( msDBP ) ≥ 95 mmHg &lt; 110 mmHg Visits 1 2 Patients treated hypertension within 4 week prior Visit 1 must msDBP ≥ 90 mmHg &lt; 110 mmHg Visit 2 All patient must msDBP ≥ 90 mmHg &lt; 110 mmHg Visit 4 Severe hypertension Pregnant nursing ( lactate ) woman Women childbearing potential Previous current diagnosis heart failure New York Heart Association ( NYHA Class IIIV ) Serum potassium ≥ 5.3 mEq/L ( mmol/L ) Visit 1 Uncontrolled Type 1 Type 2 diabetes mellitus Hypersensitivity renin inhibitor , calcium channel blocker , drug Similar chemical structure History hypertensive encephalopathy cerebrovascular accident , history transient ischemic attack ( TIA ) , myocardial infarction , coronary bypass surgery , percutaneous coronary intervention Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Aliskiren , Amlodipine , Non-responder aliskiren</keyword>
</DOC>